Summary Chronic kidney disease (CKD) due to hypertension was responsible for 9·96 million (95% UI 8·58–11·5) DALYs and 24·0% (21·0–27·3) of total CKD DALYs.
Definition This causes incorporates death and disability due to chronic kidney disease that is caused by having hypertension.
Total sources | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Incidence | 0 | |||||||||||
Prevalence | 0 | |||||||||||
Remission | 0 | |||||||||||
Causes of death | 0 | |||||||||||
Other | 354 | |||||||||||
Table 1:
Total sources used in GBD 2019 estimation
What is new in GBD 2019?
- •Excess mortality data (EMR) were modelled in MR-BRT by age and sex as a function of HAQ Index.
- •Adjustments for alternative CKD estimating equations were applied prior to DisMod-MR. These adjustments increased estimates for stage 3 but resulted in small changes for stages 4 and 5 compared to previous rounds of GBD. The reference equation is CKD-EPI.
Prevalence
|
Incidence
|
Deaths
|
YLLs
|
YLDs
|
DALYs
|
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Cases
(millions) |
Rate (per 100 000)
|
Cases
(millions) |
Rate (per 100 000)
|
Deaths
(millions) |
Rate (per 100 000)
|
YLLs
(millions) |
Rate (per 100 000)
|
YLDs
(millions) |
Rate (per 100 000)
|
DALYs
(millions) |
Rate (per 100 000)
|
|
2019 | ||||||||||||
Both Sexes | 31·6 (29·3 to 33·9) |
397·3 (369·5 to 426·4) |
1·58 (1·45 to 1·72) |
19·4 (17·8 to 21·1) |
0·450 (0·382 to 0·525) |
5·9 (4·9 to 6·8) |
8·29 (6·99 to 9·75) |
102·9 (86·9 to 121·1) |
1·67 (1·19 to 2·22) |
20·5 (14·7 to 27·4) |
9·96 (8·58 to 11·5) |
123·4 (106·9 to 142·7) |
Females | 16·1 (15·0 to 17·3) |
370·7 (344·7 to 397·2) |
0·780 (0·718 to 0·844) |
17·8 (16·4 to 19·3) |
0·218 (0·180 to 0·257) |
5·0 (4·1 to 5·9) |
3·76 (3·13 to 4·47) |
86·4 (71·9 to 102·7) |
0·810 (0·582 to 1·08) |
19·1 (13·7 to 25·4) |
4·56 (3·88 to 5·30) |
105·4 (89·9 to 122·5) |
Males | 15·5 (14·4 to 16·7) |
432·0 (400·7 to 463·7) |
0·799 (0·731 to 0·871) |
21·4 (19·7 to 23·3) |
0·232 (0·197 to 0·270) |
7·2 (6·1 to 8·2) |
4·54 (3·81 to 5·37) |
122·9 (104·0 to 144·3) |
0·859 (0·604 to 1·14) |
22·3 (15·8 to 29·7) |
5·40 (4·61 to 6·30) |
145·2 (125·3 to 168·4) |
Percentage change 2010-19 | ||||||||||||
Both Sexes | 33·4% (32·3 to 34·3) |
3·9% (3·2 to 4·5) |
36·9% (35·6 to 38·1) |
5·8% (5·1 to 6·4) |
34·1% (26·9 to 40·8) |
0·4% (–4·7 to 5·5) |
27·4% (20·1 to 34·7) |
–0·4% (–6·0 to 5·3) |
20·8% (17·9 to 23·8) |
–1·3% (–3·4 to 0·7) |
26·2% (20·1 to 32·4) |
–0·6% (–5·2 to 4·3) |
Females | 31·8% (30·5 to 32·9) |
2·9% (2·0 to 3·9) |
34·3% (32·7 to 35·9) |
4·5% (3·5 to 5·5) |
34·6% (26·1 to 43·7) |
0·9% (–5·2 to 7·4) |
28·0% (19·2 to 37·9) |
0·0% (–7·0 to 7·6) |
21·1% (18·0 to 24·5) |
–0·5% (–2·9 to 1·9) |
26·7% (19·4 to 34·9) |
–0·1% (–5·9 to 6·3) |
Males | 35·1% (34·1 to 36·1) |
4·8% (4·1 to 5·4) |
39·4% (38·1 to 40·7) |
6·7% (6·0 to 7·5) |
33·6% (24·6 to 42·2) |
–0·9% (–6·9 to 4·9) |
26·8% (17·6 to 36·3) |
–1·1% (–8·0 to 5·6) |
20·4% (17·3 to 23·6) |
–2·2% (–4·5 to 0·1) |
25·8% (18·0 to 33·7) |
–1·3% (–7·2 to 4·4) |
Numbers in parentheses are 95% uncertainty intervals. |
Table 2:
Global prevalence, incidence, deaths, YLLs, YLDs, and DALYs in counts and age-standardised rates for both sexes combined, females, and males, 2019, with percentage change between 2010 and 2019
Deaths | YLLs | YLDs | DALYs | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
1990 | 48th | 82nd | 112th | 99th | ||||||||
2010 | 32nd | 57th | 97th | 70th | ||||||||
2019 | 26th | 45th | 94th | 60th | ||||||||
Table 3:
Rank among most detailed causes for global deaths, YLLs, YLDs, and DALYs in 1990, 2010, and 2019, for both sexes combined

Figure 1:
Composition of DALYs by YLLs and constituent sequelae YLDs for both sexes combined, 2019

Figure 2:
Percentage of DALYs attributable to top risk factors for both sexes combined, 2019


Figure 3:
Age-standardised DALY rates for each location by SDI, both sexes combined, 2019

Figure 4:
Composition of DALYs by YLLs and YLDs, age group, and sex, 2019


Figure 5:
Age-standardised DALY rates (per 100 000) by location, both sexes combined, 2019